Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

y for Node-negative and 1-3 positive node Disease may Avoid ChemoTherapy) to determine the prospects of withholding chemotherapy and/or trastuzumab in HER2+, MammaPrint(R) low risk patients.

About MammaPrint(R)

MammaPrint(R) is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint(R) identifies patients with early metastasis--those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint(R) test result provides a doctor with a clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint(R) tests are conducted in Agendia's CLIA-certified service laboratory. All other breast cancer recurrence assays currently marketed have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... , WAYNE, Pa., Nov. 20 Escalon Medical Corp. ... quarter ended September 30, 2009. , For the ... or 2.7%, to $8,435,000 during the three-month period ended September ... year. The Company reported the decreased net revenue of ...
... 20 Unilens Vision Inc. (OTC Bulletin Board: UVICF; ... and markets specialty contact lenses, today reported its operating ... (FY2010). , Net sales excluding royalty income, were $1,683,673 ... reported in the previous year first quarter (FY2009). ...
Cached Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... cultural changes that promote patient safety.ENGLEWOOD, Colo., March ... technology for the safe handling, packaging and administration ... targeted campaign recognizing patient safety. The year-long ... the need for a true cultural change in ...
... Air Methods Corporation (Nasdaq: AIRM ), the ... and net income for the year and fourth quarter ended ... $498.8 million compared to $396.3 million in the prior year. ... per diluted share, in the prior year to $19.3 million, ...
... release is available in French . ... manufacturing sector specifically those working in metallurgy and ... governmental norms. , According to a new study from ... Institut national de sant publique du Qubec, extra workplace ...
... the first time that maintenance therapy with the ... (CVP) therapy improves progression-free survival in patients with stage ... of NYU Langone Medical Center, lead author of a ... Journal of Clinical Oncology . , In a ...
... No serious side effects are found in latest ... News) -- A third-generation tissue-cultured smallpox vaccine shows ... smallpox bioterrorism has prompted reconsideration of the need ... associated with first-generation vaccines #133; have raised obstacles ...
... BenefitsWATSONVILLE, Calif., March 10 For millions of Americans ... that improve health and longevity, the latest research results ... published in the scientific journal, Metabolism, found ... cholesterol.The study, conducted by David J.A. Jenkins, MD, PhD, ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 2Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 2Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 4Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 5Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 6Health News:Noisy workplaces can make workers deaf 2Health News:Study shows that maintenance rituximab is useful for advanced indolent lymphoma 2Health News:Japanese Researchers Develop New Smallpox Vaccine 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 3
... operation in the cath lab has ... daily clinical routine as cardiologists balance ... and lower costs. With AXIOM Sensis, ... system that helps to master both ...
... Artis dTC is a versatile solution designed ... department from preparation to diagnosis and ... With AXIOM Artis dTC, your cath lab ... department that leaves you free to concentrate ...
... BC is a biplane cardiovascular ... ideal for cardiological diagnostics and ... architecture enables you to optimally ... focus on:, Interventional cardiology, ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
Medicine Products: